Efficacy of topical atorvastatin for the treatment of pressure ulcers: A randomized clinical trial

Pharmacotherapy

Volumn 34, Issue 1, 2014, Pages 19-27

  Farsaei, Shadi ^a,b   Khalili, Hossein ^a   Farboud, Effat Sadat ^a   Karimzadeh, Iman ^a   Beigmohammadi, Mohammad Taghi ^c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Atorvastatin; Healing; Pressure ulcer

Indexed keywords

ATORVASTATIN; PLACEBO;

ADULT; ARTICLE; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DECUBITUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ERYTHEMA; FEMALE; HUMAN; HYPERSENSITIVITY; IRAN; MAJOR CLINICAL STUDY; MALE; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SKIN IRRITATION; STIRLING PRESSURE SORE SEVERITY SCALE; TEACHING HOSPITAL; ULCER HEALING; WOUND CARE;

ATORVASTATIN; HEALING; PRESSURE ULCER;

ADMINISTRATION, TOPICAL; AGED; CHEMISTRY, PHARMACEUTICAL; DOUBLE-BLIND METHOD; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IRAN; MALE; MIDDLE AGED; PRESSURE ULCER; PYRROLES; TREATMENT OUTCOME;

EID: 84898021825     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1339     Document Type: Article

References (46)

1. Bouten CV, Oomens CW, Baaijens FP, Bader DL. The etiology of pressure ulcers: skin deep or muscle bound? Arch Phys Med Rehabil 2003;84: 616-9.
2. Lyder CH. Pressure ulcer prevention and management. JAMA 2003;289: 223-6.
3. Graves N, Birrell F, Whitby M. Effect of pressure ulcers on length of hospital stay. Infect Control Hosp Epidemiol 2005;26: 293-7.
4. Russo CA, Steiner C, Spector W. Hospitalizations related to pressure ulcers among adults 18 years and older, 2006. HCUP Statistical Brief 64. Rockville, MD: Agency for Healthcare Research and Quality; December 2008. Available at http://www. hcup-us.ahrq.gov/reports/statbriefs/sb64.pdf. Accessed January 6, 2012.
5. Zhan C, Miller MR. Excess length of stay, charges, and mortality attributable to medical injuries during hospitalization. JAMA 2003;290: 1868-74.
6. McInnes E, Jammali-Blasi A, Bell-Syer SE, Dumville JC, Cullum N. Support surfaces for pressure ulcer prevention. Cochrane Database Syst Rev 2011;(4):CD001735.
7. Pancorbo-Hidalgo PL, Garcia-Fernandez FP, Lopez-Medina IM, Alvarez-Nieto C. Risk assessment scales for pressure ulcer prevention: a systematic review. J Adv Nurs 2006;54: 94-110.
8. Dorner B, Posthauer ME, Thomas D. The role of nutrition in pressure ulcer prevention and treatment: National Pressure Ulcer Advisory Panel white paper. Adv Skin Wound Care 2009;22: 212-21.
9. Reddy M, Gill SS, Kalkar SR, Wu W, Anderson PJ, Rochon PA. Treatment of pressure ulcers: a systematic review. JAMA 2008;300: 2647-62.
10. Farsaei S, Khalili H, Farboud ES. Potential role of statins on wound healing: review of the literature. Int Wound J 2011;9: 238-47.
11. Galeano M, Deodato B, Altavilla D, et al. Adeno-associated viral vectormediated human vascular endothelial growth factor gene transfer stimulates angiogenesis and wound healing in the genetically diabeticmouse. Diabetologia 2003;46: 546-55.
12. Diomede L, Albani D, Sottocorno M, et al. In vivo antiinflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler Thromb Vasc Biol 2001;21: 1327-32.
13. Adam O, Laufs U. Antioxidative effects of statins. Arch Toxicol 2008;82: 885-92.
14. Blanco-Colio LM, Tunon J, Martin-Ventura JL, Egido J. Anti-inflammatory and immunomodulatory effects of statins. Kidney Int 2003;63: 12-23.
15. Mach F. Statins as immunomodulatory agents. Circulation 2004;109:II15-7.
16. Jerwood S, Cohen J. Unexpected antimicrobial effect of statins. J Antimicrob Chemother 2008;61: 362-4.
17. Merx MW, Liehn EA, Janssens U, et al. HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation 2004;109: 2560-5.
18. Ginter E, Simko V. Statins: the drugs for the 21st century? Bratisl Lek Listy 2009;110: 664-8.
19. Toker S, Gulcan E, Cayc MK, Olgun EG, Erbilen E, Ozay Y. Topical atorvastatin in the treatment of diabetic wounds. Am J Med Sci 2009;338: 201-4.
20. Lait M. Wound management: a literature review. J Clin Nurs 1998;1: 11-7.
21. Sapico FL, Ginunas VJ, Thornhill-Joynes M, et al. Quantitative microbiology of pressure sores in different stages of healing. Diagn Microbiol Infect Dis 1986;5: 31-8.
22. Cutting KF, White R. Defined and refined: criteria for identifying wound infection revisited. Br J Community Nurs 2004;9: S6-15.
23. Gardner SE, Frantz RA, Troia C, et al. A tool to assess clinical signs and symptoms of localized infection in chronic wounds: development and reliability. Ostomy Wound Manage 2001;47: 40-7.
24. Herman LE, Rothman KF. Prevention, care, and treatment of pressure (decubitus) ulcers in intensive care unit patients. J Intensive Care Med 1989;4: 117-23.
25. Reid J, Morison M. Classification of pressure sore severity. Nurs Times 1994;90: 46-50.
26. Farsaei S, Khalili H, Karimzadeh I, Dashti-Khavidaki S. An old drug for a new application: potential benefits of sildenafil in wound healing. J Pharm Pharm Sci 2012;15: 483-98.
27. Olree K, Vitello J, Sullivan J, et al. Enteral formulations. In: Merritt R, ed. The ASPEN nutrition support. Practice manual. ASPEN: Silver Spring (MD), 1998: 4-1 to 4-9. 18.
28. Sevransky J. Clinical assessment of hemodynamically unstable patients. Curr Opin Crit Care 2009;15: 234-8.
29. Bours GJ, De Laat E, Halfens RJ, Lubbers M. Prevalence, risk factors and prevention of pressure ulcers in Dutch intensive care units. Results of a cross-sectional survey. Intensive Care Med 2001;27: 1599-605.
30. Goodrich C, March K. From ED to ICU: a focus on prevention of skin breakdown. Crit Care Nurs Q 1992;15: 1-13.
31. Maklebust J. Pressure ulcers: etiology and prevention. Nurs Clin North Am 1987;22: 359-77.
32. European Pressure Ulcer Advisory Panel and National Pressure Ulcer Advisory Panel. Treatment of pressure ulcers: quick reference guide. Washington, DC: National Pressure Ulcer Advisory Panel, 2009.
33. Kottner J, Raeder K, Halfens R, Dassen T. A systematic review of interrater reliability of pressure ulcer classification systems. J Clin Nurs 2009;18: 315-36.
34. Teller P, White T. The physiology of wound healing: injury through maturation. Surg Clin North Am 2009;89: 599-610.
35. Rubins JB. Alveolar macrophages: wielding the double-edged sword of inflammation. Am J Respir Crit Care Med 2003;167: 103-4.
36. Pierce G. Inflammation in nonhealing diabetic wounds: the space-time continuum does matter. Am J Pathol 2001;159: 399-403.
37. Karimian R, Nasli E, Kamali K, et al. Topical application of Semelil (ANGIPARSTM) in treatment of pressure ulcers: a randomized clinical trial. DARU J Pharm Sci 2008;16(Suppl 1): 54-57.
38. Sibbald RG, Williamson D, Orsted H, et al. Preparing the wound bed-debridement, bacterial balance, and moisture balance. Ostomy Wound Manage 2000;46: 14-35.
39. Banks MD, Graves N, Bauer JD, Ash S. The costs arising from pressure ulcers attributable to malnutrition. Clin Nutr 2010;29: 180-6.
40. Corsonello A, Garasto S, Abbatecola AM, et al. Targeting inflammation to slow or delay functional decline: where are we? Biogerontology 2010;11: 603-14.
41. Libby P, Okamoto Y, Rocha V, Folco E. Inflammation in atherosclerosis: transition from theory to practice. Circ J 2010;74: 213-20.
42. Rego ACM, Araújo Filho I, Damasceno BPGL, et al. Simvastatin improves the healing of infected skin wounds of rats. Acta Cirúrgica Brasileira 2007;22: 57-63.
43. Karadeniz Cakmak G, Irkorucu O, Ucan B, et al. Simvastatin improves wound strength after intestinal anastomosis in the rat. J Gastrointest Surg 2009;13: 1707-16.
44. Holler V, Buard V, Gaugler MH, et al. Pravastatin limits radiation- induced vascular dysfunction in the skin. J Invest Dermatol 2009;129: 1280-91.
45. Thomas DR. Prevention and treatment of pressure ulcers: what works? what doesn't? Clevel Clin J Med 2001;68: 704-7.
46. Pedley GE. Comparison of pressure ulcer grading scales: a study of clinical utility and inter-rater reliability. Int J Nurs Stud 2004;41: 129-40.